# Anti-Inflammatory Potential of Ganoderma lucidum Triterpenes: A Systematic Review and Meta-Analysis of Preclinical Evidence

**Authors:** Rafaela Guedes Pozzobon, Renata Rutckeviski, Luíza Siqueira de Lima, Cláudia Sirlene Oliveira, Fhernanda Ribeiro Smiderle

PMC · DOI: 10.3390/ph19010188 · 2026-01-21

## TL;DR

This paper reviews preclinical studies showing that Ganoderma lucidum triterpenes have strong anti-inflammatory effects, but more research is needed for clinical use.

## Contribution

The study provides a systematic review and meta-analysis of G. lucidum triterpenes' anti-inflammatory effects in preclinical models.

## Key findings

- Meta-analysis confirmed significant reductions in NO, IL-6, and TNF-α levels in vitro.
- Anti-inflammatory effects were observed in vivo in hepatic and splenic tissues.
- Downregulation of MAPK and TLR-4/NF-κB pathways was a common mechanism.

## Abstract

Background: Ganoderma lucidum triterpenes are bioactive compounds with recognized anti-inflammatory, antitumor, and immunomodulatory properties. This systematic review synthesizes evidence regarding the anti-inflammatory activity of these triterpenes based on studies from the last two decades. Methods: A systematic search was performed in PubMed, Medline, and Embase (2003–2025) for original in vitro and in vivo (non-clinical) studies evaluating G. lucidum triterpene extracts or isolated compounds. Clinical trials, reviews, and multi-species extracts were excluded. The review is registered on PROSPERO (CRD42024510982), and animal study quality was assessed using the SYRCLE Risk of Bias tool. Findings: From over 3000 records, 23 articles were included. Studies utilized diverse models, including macrophages, human PBMCs, and various animal strains (mice, rats, chickens). All studies reported significant anti-inflammatory effects via reduction in pro-inflammatory markers (TNF-α, IL-1β, IL-6), primarily through downregulation of MAPK and TLR-4/NF-κB signaling pathways. Meta-analysis of in vitro data confirmed significant reductions in NO levels (−3.29 [95% CI: −5.21, −1.37]; p = 0.0008), IL-6 (−3.51 [−4.73, −2.29]; p < 0.00001), and TNF-α (−2.20 [−2.93, −1.48]; p < 0.00001). Similar anti-inflammatory profiles were observed in vivo across hepatic and splenic tissues. Interpretation: Evidence consistently demonstrates the potent anti-inflammatory activity of G. lucidum triterpenes, highlighting their potential as therapeutic candidates for inflammatory diseases. However, the structural complexity and isomer diversity of these compounds remain significant barriers to pharmacological standardization. Future research must prioritize clinical translation by investigating compound synergism, bioavailability, and long-term toxicity profiles, which were notably absent in current non-clinical literature.

## Linked entities

- **Proteins:** TNF (tumor necrosis factor), IL1B (interleukin 1 beta), IL6 (interleukin 6), MAPK (mitogen activated kinase-like protein), TLR4 (toll like receptor 4), NFKB1 (nuclear factor kappa B subunit 1)
- **Chemicals:** NO (PubChem CID 24822)
- **Species:** Mus musculus (taxon 10090), Rattus norvegicus (taxon 10116), Homo sapiens (taxon 9606)

## Full-text entities

- **Diseases:** Inflammatory (MESH:D007249), toxicity (MESH:D064420)
- **Chemicals:** NO (MESH:D009614), G. lucidum triterpene (-), triterpenes (MESH:D014315)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606], Gallus gallus (bantam, species) [taxon 9031]

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12845357/full.md

---
Source: https://tomesphere.com/paper/PMC12845357